Axsome Therapeutics (AXSM) Free Cash Flow (2015 - 2026)

Axsome Therapeutics has disclosed Free Cash Flow across 12 years of filings, most recently posting -$20.8 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$20.8 million, up 52.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$71.0 million (up 40.26% YoY), and the FY2025 annual result was -$93.9 million, up 27.04% from the prior year.
• Free Cash Flow came in at -$20.8 million for Q1 2026 at Axsome Therapeutics, down from -$18.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $988000.0 in Q3 2025 to a low of -$55.5 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$30.2 million (2024), against an average of -$29.8 million.
• Across the five-year window, Free Cash Flow plunged 809.11% in 2024 and surged 105.28% in 2025, its largest moves.
• Axsome Therapeutics' Free Cash Flow stood at -$27.7 million in 2022, then retreated by 9.46% to -$30.4 million in 2023, then gained by 13.62% to -$26.2 million in 2024, then increased by 28.62% to -$18.7 million in 2025, then declined by 11.2% to -$20.8 million in 2026.
• The last three Free Cash Flow figures came in at -$20.8 million (Q1 2026), -$18.7 million (Q4 2025), and $988000.0 (Q3 2025), per Business Quant data.